Agilent Expands SureGuide Portfolio with CRISPR-based Products to Accelerate Disease ResearchBusiness Wire (press release)SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced the first expansion of the SureGuide poo… Continue reading
HealthLeaders Media |
Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient
HealthLeaders Media Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country’s first gene therapy, Novartis’ Kymriah, a leukemia treatment approved in August. But the total costs of Kymriah and the … |
HealthLeaders Media |
Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient
HealthLeaders Media Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country’s first gene therapy, Novartis’ Kymriah, a leukemia treatment approved in August. But the total costs of Kymriah and the … |
|
Desktop Genetics Introduces New Series of Customizable CRISPR Libraries
Technology Networks (blog) The series consists of six new CRISPR library products, each of which can be tailored to an investigator’s list of genomic targets using any delivery method. Each product addresses a particular experimental application of the genome editing technology: |
Technology Networks |
Desktop Genetics Introduces New Series of Customizable CRISPR Libraries
Technology Networks The series consists of six new CRISPR library products, each of which can be tailored to an investigator’s list of genomic targets using any delivery method. Each product addresses a particular experimental application of the genome editing technology: Agilent Expands SureGuide Portfolio with CRISPR-based Products to Accelerate Disease ResearchBusiness Wire (press release) |
Technology Networks |
Desktop Genetics Introduces New Series of Customizable CRISPR Libraries
Technology Networks The series consists of six new CRISPR library products, each of which can be tailored to an investigator’s list of genomic targets using any delivery method. Each product addresses a particular experimental application of the genome editing technology: Agilent Expands SureGuide Portfolio with CRISPR-based Products to Accelerate Disease ResearchBusiness Wire (press release) |